Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COBRA treat-to-target trial in early rheumatoid arthritis
NL-OMON19866Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Dec 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of methotrexate, prednisone, 5-aminosalicylic acid + sulphasalazine and hydroxychloroquine in rheumatoid arthritis (RA) (6 arms), sponsored by Vrije University Medical Center. Primary endpoint: Primary efficacy endpoint. Started Dec 2013; status: active, not recruiting.
02
Drugs
methotrexateprednisone5-aminosalicylic acid + sulphasalazinehydroxychloroquine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON19866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON19866.